Scholar Rock Holding Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SRRK | KROS | BBIO | CYTK | COGT | RARE | |
|---|---|---|---|---|---|---|
| Market cap | 5.61B | 214.73M | 15.17B | 8.84B | 5.46B | 1.69B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -18.6 | -1.6 | -225.0 | -14.4 | -26.3 | 76.1 |
| Price/book | 22.1 | 0.8 | -5.9 | -11.9 | 11.6 | -5.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +60.03% | −33.02% | +24.17% | +5.47% | +113.93% | −44.56% |
| Today | +4.80% | 0.00% | +5.21% | +2.07% | +1.38% | +3.19% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SRRK news ›Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they…
Scholar Rock works to bring SMA treatment to patients worldwide
‘Our work does not stop’ with US approval, says president of R&D Written by Marisa Horak, MS | Oct. 12, 2026 “Our work does not stop with the US approval,” Akshay Vaishnaw, MD, PhD, president of research and development at Scholar Rock,…
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Get Our Latest Research Report on SRRK Scholar Rock Holding Corporation NASDAQ: SRRK is a clinical-stage biopharmaceutical company focused on developing medicines that selectively target the activation of growth factors. The company's…
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
Good Manufacturing Practice (GMP) compliance means that a manufacturer follows the set of regulatory requirements and documented quality systems that ensure products are consistently produced and controlled to quality standards appropriate…
Scholar Rock (NASDAQ:SRRK) Stock Falls 5.1% – Here’s What Happened
Posted by Defense World Staff on Oct 7th, 2026 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK – Get Free Report) traded down 5.1% on Monday. The stock traded as low as $44.59 and last traded at $44.4380. Approximately 908,652…
Scholar Rock gets first FDA nod for rare muscle-wasting disease (September 11)
The U.S. Food and Drug Administration approved Scholar Rock's therapy on Friday to treat a rare genetic condition that causes muscle weakness, marking the first regulatory approval for the company. ... Scholar Rock Holding Corporation…
US FDA approves Scholar Rock's muscle weakness drug
The U.S. Food and Drug Administration on Friday approved Scholar Rock's therapy to treat a rare genetic condition that causes muscle weakness. (Reporting by Sneha S K in... Scholar Rock Holding Corporation Biotechnology & Medical Research…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net2
- defenseworld.net1
- marketbeat.com1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.